What is the annual worldwide mortality from tetanus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Annual Tetanus Deaths Worldwide

Tetanus causes approximately 56,743 deaths globally each year as of 2015, with neonatal tetanus accounting for 19,937 deaths and non-neonatal tetanus causing 36,806 deaths. 1

Global Mortality Burden

  • The most recent comprehensive global analysis from 2015 documented 56,743 total tetanus deaths worldwide (95% uncertainty interval: 48,199 to 80,042), representing the best available contemporary estimate 1

  • Of these deaths, approximately 35% (19,937 deaths) occurred in neonates, while 65% (36,806 deaths) occurred in older children and adults 1

Geographic Distribution of Deaths

The burden of tetanus mortality is heavily concentrated in resource-limited regions:

  • South Asia accounts for 45% of neonatal tetanus deaths and 47% of non-neonatal deaths, making it the highest burden region globally 1

  • Sub-Saharan Africa accounts for 44% of neonatal deaths and 36% of non-neonatal deaths 1

  • Southeast Asia contributes an additional 12% of non-neonatal tetanus deaths 1

  • The highest mortality rates (>1,000 deaths per 100,000 population for neonatal tetanus) are observed in Somalia, South Sudan, Afghanistan, and Kenya 1

Historical Context and Trends

  • Earlier estimates from 2003 suggested 309,000 total tetanus deaths annually, with neonatal tetanus alone responsible for 200,000 deaths, indicating substantial progress has been made 2

  • Between 1990 and 2015, global neonatal tetanus mortality rates dropped by 90% and non-neonatal tetanus mortality dropped by 81%, demonstrating the impact of vaccination programs 1

  • Historical data from 1951-1960 documented more than 50,000 deaths annually, though this was recognized as an underestimate due to poor surveillance in developing countries 3

Clinical Significance

  • The case-fatality ratio remains 10-20% even with modern intensive care, and can approach 100% without high-quality medical care 4, 5

  • In the United States, the case-fatality ratio declined from 18% (1998-2000) to 8.0% (2001-2016), but only 30-40 cases occur annually in this highly vaccinated population 4

  • These deaths are entirely preventable with an inexpensive and effective vaccine, yet tens of thousands continue to die annually due to inadequate immunization coverage 1

Key Caveat

The uncertainty intervals around these estimates are substantial (48,199 to 80,042 deaths), reflecting limitations in surveillance systems and vital registration in the countries with highest burden 1. The true number may be higher due to underreporting in resource-limited settings where most deaths occur.

References

Related Questions

Which of the following statements about burn patients is not true: A) burn of low temperature but long contact produces mild injury, B) epithelium (outer layer of skin) is intact with erythema (redness of the skin), C) every burned patient must receive tetanus vaccination, or D) any burn affecting the face should be referred to a burn unit?
What is the recommended tetanus prophylaxis for a patient with a dirty wound, considering options between a Tetanus (Td) shot and a Tetanus, diphtheria, and pertussis (Tdap) vaccine?
What oral antibiotic should be prescribed for an otherwise healthy adult with an infected puncture wound from a thorn bush, assuming no penicillin allergy and unknown tetanus immunization status?
How is intestinal inflammation measured?
In a healthy adult with septic bursitis (marked increase in synoviocytes), no drug allergies and no risk factors for methicillin‑resistant Staphylococcus aureus, what is the appropriate first‑line oral antibiotic regimen?
What are the recommended doses of glycopyrrolate for secretion control in an adult without contraindications, and what precautions should be taken?
How should vulvovaginitis be treated in an 8‑year‑old girl?
For an otherwise healthy adult, what are the benefits, recommended dosing, and safety considerations of NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN)?
What is the starting dose of Remeron (mirtazapine) for appetite stimulation in adults, especially older or sedation‑sensitive patients?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.